It has been well established that transformation of cells by oncogenic DNA viruses leads to the expression of virus-specific antigens, among which are the tumor-specific transplantation antigens (TSTA)4 (1–6). While the immune response to these antigens can be detected in vivo by transplantation rejection (1, 2), the procedure is time-consuming, requires a great deal of material and large numbers of animals and is difficult to quantitate.

Inhibition of macrophage migration has been a useful tool for in vitro studies of delayed hypersensitivity (7). It has been used to study this phenomenon in guinea pigs, rats, mice, hamsters and man (8, 9). Earlier studies with this technique detected reactivity against tuberculin, other microbial antigens, pure protein antigens, viral antigens, and normal tissue alloantigens (8). The test has also been used to measure cellular immunity in mice to antigens associated with Moloney sarcoma virusinduced tumors (10) and spontaneous mammary carcinoma (11), as well as to detect tumor-specific antigens of tumors induced by chemical carcinogens (12–15).


This work was supported in part by Research Grant CA 04600 from the National Cancer Institute, National Institutes of Health.


Abbreviations used in this paper: TSTA, tumor-specific transplantation antigens; TSA, tumor specific antigens; T, tumor; PE, peritoneal exudate; PFU, plaque forming units; EMEM, Eagle's medium.

This content is only available via PDF.